Bausch Health Companies Inc (BHC) Stock Price, Quote & News

Company Profile

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segm...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 514 744 6792

Website: www.bauschhealth.com

Address:

2150 St. ElzEar Boulevard West, Laval, Canada

Canuck1867 Nov. 17 at 12:31 PM

$BHC I like that RBC added another ~million + shares. NBC, Healthcare of Ontario (patient money!) still very much in...

0 · Reply

dragon_heart Nov. 17 at 1:45 AM

$HTZ $WU $BHC Trying a different scanner. 11/17/2025 short list https://x.com/dragonheart_kh/status/1990233894570922316?t=WvqcSyvSxI_vFB1A-TexVQ&s=19

0 · Reply

HedgeFollow Nov. 15 at 5:42 PM

In Q3, Paulson DOUBLED his $BHC position and bought nothing else. Now this screams high conviction. Source: https://hedgefollow.com/funds/Paulson

0 · Reply

Contrarian_Dan Nov. 14 at 7:32 PM

$BHC I'm definitely a buyer in the 5's.

1 · Reply

FU2 Nov. 14 at 6:45 PM

$BHC 95% of stocks recovered after morning sell-off. Look at this thing, pinned to the floor and slapped every time it tries to get up. MM' S doing there thing.

1 · Reply

algomezus Nov. 14 at 5:41 PM

$BHC you can't make this sht up

0 · Reply

FU2 Nov. 14 at 5:08 PM

$BHC nice 10% haircut in 2 days. POS.

0 · Reply

marketslongterm Nov. 14 at 4:53 PM

$BHC added some more here 6.32! Long term shares!

0 · Reply

Bobberty Nov. 14 at 4:24 PM

$BHC what did they say on investor day thats causing this sell-off? Crazy this finally has a decent ER and gets sold off hard after. Was hoping they'd build momentum. Guess a tiger can't change it's stripes.

1 · Reply

AKTN Nov. 14 at 3:10 PM

$BHC amazing ER pump and dump.

0 · Reply

Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical

Nov 13, 2025, 7:00 AM EST - 4 days ago

Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day

Nov 11, 2025, 7:07 AM EST - 6 days ago

Bausch Health: Solid Q3 Performance Reinforces Deleveraging Path

Nov 5, 2025, 8:00 AM EST - 12 days ago

Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease

Nov 3, 2025, 4:30 PM EST - 13 days ago

Bausch + Lomb to Hold Investor Day on Nov. 13

Oct 31, 2025, 7:45 AM EDT - 17 days ago

Why Bausch Health Is A Buy After Rising 10% On Third-Quarter Results

Oct 29, 2025, 8:26 PM EDT - 18 days ago

Bausch Health Companies Inc. (BHC) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:05 PM EDT - 18 days ago

Bausch Health Announces Third Quarter 2025 Results

Oct 20, 2025, 10:57 AM EDT - 27 days ago

Activist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + Lomb

Oct 9, 2025, 7:00 AM EDT - 5 weeks ago

Bausch Health Announces Results of Special Meeting of Shareholders

Sep 30, 2025, 8:00 AM EDT - 6 weeks ago

Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV

Sep 30, 2025, 7:00 AM EDT - 6 weeks ago

Bausch Health to Announce Third Quarter 2025 Results on October 29

Sep 29, 2025, 8:00 AM EDT - 7 weeks ago

Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry

Sep 11, 2025, 12:04 PM EDT - 2 months ago

Bausch Health: Repricing Continues As Deleveraging Gains Traction

Sep 11, 2025, 8:35 AM EDT - 2 months ago

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

Sep 11, 2025, 7:00 AM EDT - 2 months ago

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

Sep 9, 2025, 7:00 AM EDT - 2 months ago

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

Sep 5, 2025, 8:02 AM EDT - 2 months ago

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System

Aug 26, 2025, 8:00 AM EDT - 2 months ago

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

DRRX

Aug 21, 2025, 8:02 AM EDT - 3 months ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

Aug 18, 2025, 5:48 PM EDT - 3 months ago

Bausch + Lomb board members resign after Icahn agreement ends

Aug 15, 2025, 2:30 PM EDT - 3 months ago

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes

Aug 12, 2025, 1:02 PM EDT - 3 months ago

Why Bausch Health Stock Surged By Nearly 20%

Aug 7, 2025, 8:00 AM EDT - 3 months ago

Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners

Jul 30, 2025, 11:30 PM EDT - 3 months ago

Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:05 PM EDT - 3 months ago

Bausch Health Announces Second Quarter 2025 Results

Jul 29, 2025, 2:21 PM EDT - 3 months ago

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

DRRX

Jul 29, 2025, 7:00 AM EDT - 3 months ago

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

DRRX

Jul 29, 2025, 7:00 AM EDT - 3 months ago

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

Jul 28, 2025, 9:10 AM EDT - 4 months ago

Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand

Jul 24, 2025, 8:02 AM EDT - 4 months ago

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

Jul 10, 2025, 5:00 PM EDT - 4 months ago

CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs

Jul 10, 2025, 4:15 PM EDT - 4 months ago

Bausch Health Appoints New Chief Accounting Officer

Jul 9, 2025, 8:00 AM EDT - 4 months ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs

Jul 7, 2025, 8:00 AM EDT - 4 months ago

Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence

Jul 2, 2025, 7:00 AM EDT - 4 months ago

Bausch Health to Announce Second Quarter 2025 Results on July 30

Jun 26, 2025, 4:30 PM EDT - 5 months ago

Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility

Jun 22, 2025, 5:00 AM EDT - 5 months ago

A Billionaire Trump Supporter Is Buying These Two Stocks

PPTA

Jun 18, 2025, 11:01 AM EDT - 5 months ago

Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in Shares

Jun 16, 2025, 4:04 AM EDT - 5 months ago

Repricing Potential Driven By Deleveraging

Jun 4, 2025, 6:59 AM EDT - 5 months ago

Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

May 21, 2025, 9:45 AM EDT - 6 months ago

Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players - Allergan, Bausch Health, Bloomage Biotechnology, and Galderma

May 21, 2025, 6:59 AM EDT - 6 months ago

Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States

May 14, 2025, 4:15 PM EDT - 6 months ago

Bausch Health Announces 2025 Annual Meeting of Shareholder Results

May 14, 2025, 6:59 AM EDT - 6 months ago

Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States

May 7, 2025, 7:00 AM EDT - 6 months ago

Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens

May 6, 2025, 8:00 AM EDT - 6 months ago

Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization

Apr 30, 2025, 7:51 PM EDT - 7 months ago

Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 4:05 PM EDT - 7 months ago

Bausch Health Announces First Quarter 2025 Results

Apr 29, 2025, 8:00 AM EDT - 7 months ago

Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System

Canuck1867 Nov. 17 at 12:31 PM

$BHC I like that RBC added another ~million + shares. NBC, Healthcare of Ontario (patient money!) still very much in...

0 · Reply

dragon_heart Nov. 17 at 1:45 AM

$HTZ $WU $BHC Trying a different scanner. 11/17/2025 short list https://x.com/dragonheart_kh/status/1990233894570922316?t=WvqcSyvSxI_vFB1A-TexVQ&s=19

0 · Reply

HedgeFollow Nov. 15 at 5:42 PM

In Q3, Paulson DOUBLED his $BHC position and bought nothing else. Now this screams high conviction. Source: https://hedgefollow.com/funds/Paulson

0 · Reply

Contrarian_Dan Nov. 14 at 7:32 PM

$BHC I'm definitely a buyer in the 5's.

1 · Reply

FU2 Nov. 14 at 6:45 PM

$BHC 95% of stocks recovered after morning sell-off. Look at this thing, pinned to the floor and slapped every time it tries to get up. MM' S doing there thing.

1 · Reply

algomezus Nov. 14 at 5:41 PM

$BHC you can't make this sht up

0 · Reply

FU2 Nov. 14 at 5:08 PM

$BHC nice 10% haircut in 2 days. POS.

0 · Reply

marketslongterm Nov. 14 at 4:53 PM

$BHC added some more here 6.32! Long term shares!

0 · Reply

Bobberty Nov. 14 at 4:24 PM

1 · Reply

AKTN Nov. 14 at 3:10 PM

$BHC amazing ER pump and dump.

0 · Reply

greyfox Nov. 14 at 2:30 PM

$BHC You have to love this stock as steady in this crappy market. Now, lets get this thing well into the 7s and soon. Perhaps today?

1 · Reply

Drrxgernbcrx Nov. 13 at 5:44 PM

$BHC Anyone watch the investor day see a mention of Durect DRRX larsucosterol formerly DR928 acquisition, timing of development, and projected peak revenue?

1 · Reply

Drrxgernbcrx Nov. 13 at 5:21 PM

$BHC For those who watched investor day, any mention of durect drrx acquisition, larsucosterol development 0lans or timing, and projected revenue at peak for larsucosterol gormerly DR928?

0 · Reply

marketslongterm Nov. 13 at 1:18 AM

$BHC added some more to my bags! Long term hold target 7x returns from current price. 5yrs!

1 · Reply

algomezus Nov. 12 at 9:15 PM

$BHC I likey likey the last two days!!

0 · Reply

CindyH0o Nov. 12 at 8:59 PM

$BHC massive volume?

0 · Reply

vjtweet Nov. 12 at 8:48 PM

$BHC long today.

0 · Reply

algomezus Nov. 12 at 5:53 PM

$BLCO $BHC let go BLCO my estranged offspring get to 17.

0 · Reply

FU2 Nov. 12 at 3:11 PM

$BHC volume is higher today, hope its a good sign

0 · Reply

AKTN Nov. 10 at 8:04 PM

$BHC this stock will make you a millionaire, you don't even need to be patient and already have a billion dollars.

0 · Reply

FU2 Nov. 10 at 8:03 PM

$BHC who believes this is selling off because its a POS or totally price manipulated. Earnings were far, BLCO 3 month chart looks good. Just nothing has added up for 3 years here now. Next stop $6 flat.

0 · Reply

algomezus Nov. 10 at 7:59 PM

$BHC WTF

0 · Reply

Market Cap	2.33B
Revenue (ttm)	9.63B
Net Income (ttm)	-46.00M
EPS (ttm)	N/A
PE Ratio	1.74
Forward PE	1.72
Profit Margin	-0.48%
Debt to Equity Ratio	59.11

Volume	2,255,700
Avg Vol	2,121,680
Day's Range	N/A - N/A
Shares Out	370.85M
Stochastic %K	4%
Beta	0.47
Analysts	Hold
Price Target	$7.17